Longeveron Inc. (LGVN)
| Market Cap | 21.71M +74.0% |
| Revenue (ttm) | 1.19M -42.7% |
| Net Income | -23.47M |
| EPS | -9.73 |
| Shares Out | 3.19M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 41,236 |
| Open | 6.54 |
| Previous Close | 6.58 |
| Day's Range | 6.53 - 6.88 |
| 52-Week Range | 4.75 - 12.30 |
| Beta | -0.26 |
| Analysts | Buy |
| Price Target | 71.50 (+949.93%) |
| Earnings Date | Aug 12, 2026 |
About LGVN
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer’s disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated... [Read more]
Financial Performance
In 2025, Longeveron's revenue was $1.20 million, a decrease of -49.87% compared to the previous year's $2.39 million. Losses were -$22.70 million, -7.79% less than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for LGVN stock is "Buy." The 12-month stock price target is $71.5, which is an increase of 949.93% from the latest price.
News
Longeveron to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Longeveron to present at the H.C. Wainwright 28th Annual Global Investment Conference taking place September 14-16, 2026; presentation 9/14/26 at 1:00pm ET
Longeveron Inc trading halted, news pending
19:50 EDT Longeveron (LGVN) Inc trading halted, news pending
Longeveron announces 1-for-10 reverse stock split
Longeveron (LGVN) announced that the company will undertake a 1-for-10 reverse split of the company’s Class A common stock, par value $0.001 per share and Class B common stock, par…
Longeveron Announces 1-for-10 Reverse Stock Split
MIAMI, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-relat...
Longeveron CFO Marie Washburn to switch roles, Nirav Jhaveri to succeed
Longeveron (LGVN) announced that the company has appointed Nirav Jhaveri to the company’s executive leadership team in the role of CFO, principal financial officer and principal accounting officer. He...
Longeveron Appoints Nirav Jhaveri as Chief Financial Officer
Mr. Jhaveri has over 25 years of experience in capital markets, corporate finance, business development and investor relations, including more than 15 years in the biotech sector MIAMI, Aug. 19, 2026 ...
Longeveron reports Q2 EPS (19c) vs. (33c) last year
Reports Q2 revenue $287,000 vs. $316,000 last year. “Longeveron (LGVN) is approaching a series of potentially transformative milestones across our four stem cell therapy development programs that have...
Longeveron Earnings Call Transcript: Q2 2026
Q2 2026 saw a 10% revenue decline and a net loss increase to $6.1 million, with cash runway into Q4 2026. Key milestones include the upcoming ELPIS II data readout for HLHS and recognition as an XPRIZE Healthspan finalist, supporting partnership and regulatory strategies.
Longeveron Quarterly report: Q2 2026
Longeveron has published its Q2 2026 quarterly earnings report on August 12, 2026.
Longeveron Earnings release: Q2 2026
Longeveron released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
Longeveron Announces 2026 Second Quarter Financial Results and Provides Business Update
On track for September 2026 top-line results from Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for hypoplastic left heart syndrome (HLHS), a rare pediat...
Longeveron Slides: Investor presentation
Longeveron has posted slides in relation to its latest quarterly earnings report, which was published on August 12, 2026.
Longeveron Named a Finalist Team and Will Receive a $1,000,000 Milestone 2 Award for the XPRIZE Healthspan Global Competition
Longeveron selected as a Milestone 2 Awardee based on published clinical trial results which demonstrated laromestrocel increased 6-minute walk distance in patients with Aging-related Frailty MIAMI, A...
Longeveron to Report 2026 Second Quarter Financial Results and Host Conference Call on August 12, 2026
MIAMI, Fla., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chron...
Deborah D. Ascheim, M.D. Elected to Longeveron Board of Directors
MIAMI, July 23, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-relate...
Longeveron presents positive laromestrocel data in Alzheimer’s disease
Longeveron (LGVN) announced the presentation of additional data from its Phase 2a CLEAR-MIND clinical trial of laromestrocel in patients with mild Alzheimer’s disease. The findings, presented at the A...
Longeveron Announces Presentation of Clinical Data at the 2026 Alzheimer's Association International Conference (AAIC) that Indicate Its Cellular Therapy Laromestrocel Reduced Neuroinflammation in Patients with Alzheimer's Disease
Poster Presentation at the 2026 Alzheimer's Association International Conference (AAIC) entitled “Laromestrocel Stabilizes Brain Inflammation In Key Alzheimer's Disease Gray And White Matter Regions A...
Longeveron appoints Marie Washburn CFO
Longeveron (LGVN) announced that the company has appointed Marie Washburn to the company’s executive leadership team in the role of senior VP and CFO, principal financial officer and principal account...
Longeveron® Appoints Marie Washburn as Chief Financial Officer
Ms. Washburn has over 20 years of experience in leadership roles in the pharmaceutical and biotech sectors Corporate focus on delivering top-line results from the Phase 2b clinical trial evaluating it...
Longeveron Transcript: AGM 2026
The meeting covered director elections, share authorization increases, a reverse stock split, incentive plan amendments, and auditor ratification. All proposals passed by majority vote, and voting results will be reported on Form 8-K. Questions from stockholders will be answered online.
New Phase 2a Clinical Data Analysis of Stem Cell Therapy Laromestrocel in Mild Alzheimer's Disease Accepted for Poster Presentation at the 2026 Alzheimer's Association International Conference (AAIC)
MIAMI, June 18, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-relat...
Longeveron granted SME status by European Medicines Agency
Longeveron (LGVN) announced that the company has been granted small or medium-sized enterprise, or SME, status by the European Medicines Agency, or EMA, which offers benefits leading up to and…
Longeveron Granted Small or Medium-sized Enterprise (SME) Status by the European Medicines Agency (EMA)
MIAMI, June 09, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-relat...
Longeveron to Present at BIO International Convention 2026
Longeveron will present at BIO 2026. CEO, CFO & BD will host meetings to explore partnership opportunities for its 4 stem cell therapy developmet programs.
Longeveron Issues Letter to Stockholders Highlighting Corporate Strategy, Strategic Partnering Approach and 2026 Key Priorities
MIAMI, May 20, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-relate...